ArticleUltrasonics sonochemistry2026
Real-time drug release monitoring from acoustically responsive scaffolds.
Article in Ultrasonics sonochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ultrasound-responsive composite hydrogels: Design rules for spatiotemporally controlled drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Acoustically responsive scaffolds (ARSs), composite hydrogels containing phase-shift droplets that are activated by ultrasound, enable on-demand drug delivery with spatiotemporal precision. Yet, real-time monitoring of drug release from ARSs remains limited. Here, we studied the dynamics of the ultrasound-based activation mechanism, acoustic droplet vaporization (ADV), in fibrin-based ARSs containing perfluorohexane droplets. We investigated how initial droplet concentration, acoustic pressure, and burst number affect droplet dynamics, bubble cloud evolution, acoustic emissions, and drug release efficiency. Optical imaging, at 5 million frames per second (Mfps) and 50 fps, revealed that ADV-induced bubble cloud morphologies were concentration dependent. At high concentrations and pressures, bubble clouds expanded significantly beyond the ultrasound focal region by up to 300%. ADV generated distinct low-frequency (LF) emissions that progressively decreased over repeated bursts by ≈30 dB, indicating a reduction in the number of vaporized droplets within the focal region. The burst number at which LF emissions plateaued (e.g., 51 bursts at 0.1% (v/v), 6.2 MPa) correlated with the burst number at which payload release reached its maximum value (57 bursts), demonstrating that LF emissions provide real-time, non-invasive feedback on ADV-mediated drug delivery. These results establish a direct correlation between LF emissions and ADV, and underscore their potential for real-time monitoring of drug release in ARSs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.